Dr. Ramalingam on Side Effects Associated With Immunotherapy in Lung Cancer

Subcutaneous pembrolizumab plus chemotherapy was noninferior to IV pembrolizumab plus chemotherapy in treatment-naïve non-small cell lung cancer.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The FDA extended the Prescription Drug User Fee Act date for the biologics license application seeking approval of zenocutuzumab for NRG1-positive lung and pancreatic cancer.

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer treated with pralsetinib.